[Medical treatment of endometriosis: Hormonal treatment of pain, impact on evolution and future perspectives]

Geoffron S, Sophie Geoffron, Guillaume Legendre, Legendre G, Emile Daraï, Daraï E, Émile Daraï, Chabbert-Buffet N, Nathalie Chabbert-Buffet, Nathalie Chabbert‐Buffet
Presse medicale (Paris, France : 1983) · 2017 · vol. 46(12) , pp. 1199–1211 · doi:10.1016/j.lpm.2017.10.005 · PMID:29133081 · W2767669816
Review OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This paper reviews hormonal treatments for endometriosis, focusing on managing pain and lesion progression while exploring future therapeutic options.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

CONTEXT: Endometriosis is a chronic painful disease, for which hormone therapy is usually offered as a first line option to women not willing to conceive. OBJECTIVES: To analyse and synthesize the literature, from 2006 onwards, on pain control, and disease evolution in oemn using combined hormonal contraceptives, progestins and GnRH analogs. Data on other current and future treatment perspectives is included as well. SOURCES: Medline (Pubmed), the Cochrane Library, and endometriosis treatment recommendations published by European Society of Human Reproduction and Embryology (ESHRE), National Institute for health and Care Excellence (NICE), American College of Obstetricians and Gynecologists (ACOG), Royal College of Obstetricians and Gynaecologists (RCOG) and Société des Obstétriciens et Gynécologues du Canada (SOGC). STUDY SELECTION: Meta-analysis and clinical trials are included. RESULTS: Study quality is heterogeneous in general. Hormone therapy inconstantly allows pain relief and prevention of endometrioma and rectovaginal wall nodules recurrence. Available molecules and routes of administration as well as risk benefit balance are evaluated. Data on future perspectives are limited to date and do not allow use in routine. CONCLUSION: Hormonal treatment of endometriosis relies on combined hormonal contraceptives (using different routes of administration), progestins and particularly the levonorgestrel-releasing IUS, and GnRH analogs as a last option, in combination with an add-back therapy. Promising alternatives are currently under preclinical and clinical evaluation.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Disease Progression Disease Progression Drug Combinations Drug Combinations Endometriosis Endometriosis Endometriosis Ethinyl Estradiol Ethinyl Estradiol Ethinyl Estradiol Female Female Forecasting Forecasting Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (5)

SciLite annotations

chemicals 4
progestin hormone progestin levonorgestrel
organisms 1
human

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:20:50.926721+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
unpaywall
last seen: 2026-10-11T06:28:45.473802+00:00
License: CC0 · commercial use OK